$SRPT "Jericho has received approval for a gene therapy that is changing the course for boys with this disease called #Elevidys." 💪 "Support Jericho's Fight Against #Duchenne" gofundme.com/f/support-jeri…

Research at #USCSchaeffer projects Medicare coverage of #obesity treatments could generate $4T in social benefit to Americans over 3 decades. Drugs may not pay for themselves in the short term, but they can provide tremendous value to patients over time. healthpolicy.usc.edu/article/cbo-re…

$SRPT profile: Douglas Ingram, JD; President and Chief Executive Officer, Sarepta Therapeutics Therapeutics: "Sarepta has achieved compounded annual revenue growth of approximately 40% as it has matured into a profitable, cash flow positive organization." 💪 healthpolicy.usc.edu/advisory-board…

$HNSA Enrolment in the SRP-9001-104 Phase 1b trial continues.. evaluating #imlifidase as a pre-treatment to $SRPT's ELEVIDYS (delandistrogene moxeparvovec) gene therapy in Duchenne Muscular Dystrophy (DMD). The companies expect to share preliminary data from the trial in 2025.

$SRPT "They don't the luxury of time to make a decision or wait for different therapies, and I think that the progressive nature of Duchenne muscular dystrophy or SMA is really driving their gene therapy uptake." #Elevidys ajmc.com/view/sickle-ce…

$SRPT "biotech investors don't like such delays, even if, in this case, it was less than a month" 😂 "So, the stock likely hasn't peaked." 😃 theglobeandmail.com/investing/mark…

Bofa:" $SRPT Takeaways from our visit to Sarepta’s Headquarters: Mgmt is confident in the Elevidys cadence and guidance We hosted $SRPT ’s CEO, CFO and CSO. Mgmt reiterated their confidence in the revenue guidance highlighting the depth of their expertise in DMD launches. They

What a story. But the sad part is to read that people saw his life as "waisted". I have worked with Duchenne children and each precious child I was allowed to meet won a special place in my heart, while living their short lives in turbo speed.